|
KMID : 1037120140320030145
|
|
The World Journal of Men′s Health
2014 Volume.32 No. 3 p.145 ~ p.150
|
|
|
The Efficacy of Mirodenafil for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Middle-Aged Males
|
|
Kong Do-Hoon
Yun Chang-Jin
Park Hyun-Jun
Park Nam-Cheol
|
|
|
Abstract
|
|
|
Purpose: The aim of this study was to investigate the efficacy of mirodenafil in middle-aged male patients with chronic
prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Materials and Methods: Eighty-eight males with CP/CPPS were randomized to receive either levofloxacin (500 mg/d) (group L, 40 patients) or levofloxacin (500 mg/d) and mirodenafil (50 mg/d) (group ML, 48 patients) for six weeks. The International Prostate Symptom Score (IPSS), National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and erectile function (EF)domain scores of the International Index of Erectile Function (IIEF) questionnaire were used to grade symptoms at baseline and 6 weeks after treatment.
Results: The mean change in total IPSS from baseline was higher in group ML than that in group L (group L, ?1.1 vs. group ML, ?4.3; p＜0.05). Significant improvements were also seen in the IPSS voiding subscore (group L, ?0.7 vs. group ML, ?3.0; p＜0.05). Changes observed in the NIH-CPSI of group ML at six weeks were greater than those at baseline (group L, ?3.2 vs. group ML, ?7.2; p＜0.05). Significant improvements were seen in the NIH-CPSI voiding (group L, ?0.5 vs. group ML, ?1.7; p＜0.05) and quality of life domains (group L, ?1.0 vs. group ML, ?1.8; p＜0.05). Group ML showed a significantly greater increase in the IIEF-EF score than did group ML (group L, +0.2 vs. group ML, +7.8; p＜0.05).
Conclusions: Mirodenafil (50 mg once daily) was well tolerated and resulted in significant symptomatic improvement in
middle-aged males with CP/CPPS.
|
|
|
KEYWORD
|
|
|
Chronic prostatitis with chronic pelvic pain syndrome, Erectile dysfunction, Phosphodiesterase 5 inhibitors, Treatment outcome
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|
|